Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged 60 Years for 24 Months.
Status:
RECRUITING
Trial end date:
2027-01-30
Target enrollment:
Participant gender:
Summary
People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (ART), allowing them to stabilize the HIV-infection and to live a normal life despite the infection. The present study is encouraged to demonstrate that efficacy and security of CAB LA + RPV LA treatment's on this population remains the same compared to younger population of patients. This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.
Phase:
PHASE4
Details
Lead Sponsor:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia